A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase of Trial: Phase 0
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2017 Planned End Date changed from 1 Jul 2019 to 1 Jun 2019.
- 13 Jun 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Jun 2019.